Medco hires FDA genomics expert
Executive Summary
Felix Frueh joins Medco as VP-R&D, personalized medicine. He had been associate director for genomics in the FDA's Office of Clinical Pharmacology since 2004. While at the agency, Frueh was responsible for developing policy on pharmacogenomics. He also chaired FDA's Interdisciplinary Pharmacogenomics Review Group. In the new position at Medco, he will advance research in genetic testing aimed at improving the precision of pharmacy care and will develop the firm's Personalized Medicine Research Center, under construction in Whitestown, Ind. Medco currently is collaborating with the Mayo Clinic and Lab Corp. on genetic research on improving treatment with warfarin and tamoxifen (1"The Pink Sheet," Nov. 26, 2007, p. 11)
You may also be interested in...
Warfarin Dosing Issues Emerge In Early Results From Medco/Mayo Research
Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its analyst day presentation Nov. 16
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.